Investment in Transchem Limited Warrants	6 Months Ended
Jun. 30, 2026
Investments, All Other Investments [Abstract]
Investment in Transchem Limited Warrants	Investment in Transchem Limited Warrants On June 3, 2026 (the "allotment date"), Opco was allotted 47,500,000 warrants (the “Transchem Warrants”) to subscribe for equity shares of Transchem Limited (“Transchem”), an Indian company listed on the BSE Limited, on a preferential basis under the SEBI (ICDR) Regulations, 2018. The Company paid upfront subscription consideration of 25% of the total warrant issue price, or ₹18.75 per warrant (approximately $9,409,784 in the aggregate at the transaction-date exchange rate), with the remaining 75% (₹56.25 per warrant, or approximately $28,258,858 in the aggregate at the June 30, 2026 exchange rate) payable only upon exercise. Each Transchem Warrant is exercisable on a 1-for-1 basis into a Transchem equity share and expires 18 months from the allotment date. Upon full exercise, and absent other capital changes at Transchem, the Company's holding would represent approximately 64.4% of Transchem's fully diluted equity. For the three and six months ended June 30, 2026, the Company recognized an unrealized gain of approximately $98.3 million related to the change in fair value of the Transchem Warrants during the period in which they were held.

Investment in Transchem Limited Warrants

6 Months Ended

Jun. 30, 2026

Investments, All Other Investments [Abstract]

Investment in Transchem Limited Warrants

On June 3, 2026 (the "allotment date"), Opco was allotted 47,500,000 warrants (the “Transchem Warrants”) to subscribe for equity shares of Transchem Limited (“Transchem”), an Indian company listed on the BSE Limited, on a preferential basis under the SEBI (ICDR) Regulations, 2018. The Company paid upfront subscription consideration of 25% of the total warrant issue price, or ₹18.75 per warrant (approximately $9,409,784 in the aggregate at the transaction-date exchange rate), with the remaining 75% (₹56.25 per warrant, or approximately $28,258,858 in the aggregate at the June 30, 2026 exchange rate) payable only upon exercise. Each Transchem Warrant is exercisable on a 1-for-1 basis into a

Transchem equity share and expires 18 months from the allotment date. Upon full exercise, and absent other capital changes at Transchem, the Company's holding would represent approximately 64.4% of Transchem's fully diluted equity.

For the three and six months ended June 30, 2026, the Company recognized an unrealized gain of approximately $98.3 million related to the change in fair value of the Transchem Warrants during the period in which they were held.